SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

Search

BioMerieux

Closed

SectorHealthcare

121.4 1.08

Overview

Share price change

24h

Current

Min

120.2

Max

121.8

Key metrics

By Trading Economics

Income

1.6M

217M

Sales

785M

P/E

Sector Avg

32.582

51.198

Dividend yield

0.76

Profit margin

10.438

Employees

14,147

EBITDA

161M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+8.71% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.76%

2.40%

Next Earnings

4 Sept 2025

Market Stats

By TradingEconomics

Market Cap

461M

14B

Previous open

120.32

Previous close

121.4

News Sentiment

By Acuity

55%

45%

326 / 380 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

BioMerieux Chart

Past performance is not a reliable indicator of future results.

Related News

17 Apr 2025, 08:49 UTC

Major Market Movers

BioMerieux Shares Fall After Warning on Currency-Exchange Hit

Peer Comparison

Price change

BioMerieux Forecast

Price Target

By TipRanks

8.71% upside

12 Months Forecast

Average 131 EUR  8.71%

High 140 EUR

Low 125 EUR

Based on 4 Wall Street analysts offering 12 month price targets forBioMerieux - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

3

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

113.1 / 118.6Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

326 / 380 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About BioMerieux

bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated Identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST Gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDASB·R·A·H·M·S PCTTM, a specific marker of severe bacterial infections/sepsis. It also provides Biomérieux vision suite, a software that provides actionable information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE Monoplex PCR tests; NUCLISENS ranges, a product for automation of the molecular biology laboratory and extraction; EMAG system For DNA and RNA extraction; ESTREAM, an automated preparation station for samples to process PCR tests; GENE-UP and VERIFLOW ranges for detection of microorganisms for the food industry. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.